Singer P A, Thiel E C, Naylor C D, Richardson R M, Llewellyn-Thomas H, Goldstein M, Saiphoo C, Uldall P R, Kim D, Mendelssohn D C
Centre for Bioethics, University of Toronto, Ontario, Canada.
J Am Soc Nephrol. 1995 Nov;6(5):1410-7. doi: 10.1681/ASN.V651410.
The purpose of this study was to describe the life-sustaining treatment preferences of dialysis patients and to compare the acceptability of two generic and a disease-specific advance directive (AD). Of 532 potentially eligible hemodialysis patients, 95 (17.9%) participated in the study. These patients completed two generic (the Centre for Bioethics Living Will and the Medical Directive) and one disease-specific (the Dialysis Living Will) AD in a randomized cross-over trial. Treatment preferences were measured by using the Centre for Bioethics Living Will. Acceptability of the AD was measured by using a 13-item advance directive acceptability questionnaire (ADAQ) for each AD, and the advance directive choice questionnaire (ADCQ) to elicit participants' preferred AD. Twenty-five percent of the participants wanted to continue dialysis in case of severe stroke, 19% in severe dementia, and 14% in permanent coma. Averaged across treatments, proportions of participants wanting treatment in various health states were: current health (86%), mild stroke (84%), moderate stroke (60%), severe stroke (21%), mild dementia (78%), moderate dementia (51%), severe dementia (14%), terminal illness (41%), and permanent coma (10%). Averaged across health states, proportions of participants wanting various types of treatment were: dialysis (58%), antibiotics (53%), transfusion (53%), surgery (48%), cardiopulmonary resuscitation (48%), respirator (47%), and tube feeding (41%). Mean ADAQ scores were: Dialysis Living Will, 71%; Centre for Bioethics Living Will, 70%; and Medical Directive, 60% (F = 8.27, P < 0.001 (repeat measures analysis of variance); the Dialysis Living Will and Centre for Bioethics Living Will scored significantly higher than the Medical Directive). The proportion of participants who said they would choose to complete each AD was: Dialysis Living Will, 28%; Centre for Bioethics Living Will, 38%; Medical Directive, 31%; and unsure, 3% (chi 2 = 1.465, df = 2, P = 0.48). In conclusion, twenty-five percent or less of hemodialysis patients want to continue dialysis in three specific health states: severe stroke, severe dementia, and permanent coma. Health states and illness severity, far more than treatment descriptions, influence preferences. Dialysis patients should be offered a generic AD, and some generic AD are more acceptable than others. Only a minority of dialysis patients will complete any AD, but the completion of written AD forms is only one element in the process of advance care planning.
本研究的目的是描述透析患者维持生命治疗的偏好,并比较两种通用型和一种疾病特异性预先指示(AD)的可接受性。在532名潜在符合条件的血液透析患者中,95名(17.9%)参与了研究。这些患者在一项随机交叉试验中完成了两份通用型(生物伦理中心生前遗嘱和医疗指示)和一份疾病特异性(透析生前遗嘱)预先指示。通过使用生物伦理中心生前遗嘱来衡量治疗偏好。通过使用一份针对每份预先指示的包含13个条目的预先指示可接受性问卷(ADAQ)以及预先指示选择问卷(ADCQ)来引出参与者偏好的预先指示,以此衡量预先指示的可接受性。25%的参与者表示在发生严重中风时希望继续透析,19%在严重痴呆时希望继续透析,14%在永久性昏迷时希望继续透析。在各种治疗情况下进行平均,希望在不同健康状态下接受治疗的参与者比例分别为:当前健康状态(86%)、轻度中风(84%)、中度中风(60%)、严重中风(21%)、轻度痴呆(78%)、中度痴呆(51%)、严重痴呆(14%)、晚期疾病(41%)以及永久性昏迷(10%)。在各种健康状态下进行平均,希望接受各种类型治疗的参与者比例分别为:透析(58%)、抗生素(53%)、输血(53%)、手术(48%)、心肺复苏(48%)、呼吸器(47%)以及鼻饲(41%)。ADAQ的平均得分分别为:透析生前遗嘱71%;生物伦理中心生前遗嘱70%;以及医疗指示60%(F = 8.27,P < 0.001(重复测量方差分析);透析生前遗嘱和生物伦理中心生前遗嘱的得分显著高于医疗指示)。表示会选择完成每份预先指示的参与者比例分别为:透析生前遗嘱28%;生物伦理中心生前遗嘱38%;医疗指示31%;不确定3%(卡方 = 1.465,自由度 = 2,P = 0.48)。总之,25%或更少的血液透析患者希望在三种特定健康状态下继续透析:严重中风、严重痴呆和永久性昏迷。健康状态和疾病严重程度对偏好的影响远远超过治疗描述。应向透析患者提供通用型预先指示,并且某些通用型预先指示比其他的更可接受。只有少数透析患者会完成任何预先指示,但书面预先指示表格的填写只是预先护理计划过程中的一个要素。